LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Slēgts

30.3 0.03

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

29.89

Max

31.06

Galvenie mērījumi
By Trading Economics
Ienākumi	-30M -30M
Pārdošana	-26M 77M
Peļņas marža	-38.823
Darbinieki	524
EBITDA	-12M -8M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+119.74% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-214M 1.4B
Iepriekšējā atvēršanas cena	30.27
Iepriekšējā slēgšanas cena	30.3

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. maijs 23:58 UTC

Peļņas

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026. g. 7. maijs 22:57 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026. g. 7. maijs 23:52 UTC

Peļņas

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026. g. 7. maijs 23:45 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 7. maijs 23:39 UTC

Tirgus saruna

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026. g. 7. maijs 23:28 UTC

Tirgus saruna

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026. g. 7. maijs 23:11 UTC

Peļņas

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026. g. 7. maijs 23:06 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026. g. 7. maijs 23:05 UTC

Peļņas

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026. g. 7. maijs 23:04 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026. g. 7. maijs 23:02 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026. g. 7. maijs 23:00 UTC

Tirgus saruna

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026. g. 7. maijs 22:42 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026. g. 7. maijs 22:33 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026. g. 7. maijs 22:32 UTC

Peļņas

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie: 68% of FY Income From International >MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026. g. 7. maijs 22:29 UTC

Peļņas

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026. g. 7. maijs 22:26 UTC

Peļņas

Macquarie to End Share Buyback Extended in November>MQG.AU

2026. g. 7. maijs 22:25 UTC

Peļņas

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

119.74% augšup

Prognoze 12 mēnešiem

Vidējais 62.67 USD 119.74%

Augstākais 100 USD

Zemākais 33 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.